Back to results
US 9,848,604 B2Granted
Antimicrobial wash
AssigneeMedtronic Xomed, Inc.
InventorsJie Wen, Dana A. Oliver
Life of this patent
Estimating the term…
Abstract
A method for detaching, removing or otherwise disrupting bacteria or biofilm by applying with pressure an antimicrobial wash. The antimicrobial wash contains a biguanide compound or mixtures thereof.
Claims28
A method for removing biofilm comprising:
- applying with pressure of about 30,000 Pascal (4.4 psi) to about 480,000 Pascal (70 psi) an antimicrobial wash comprising a biguanide compound or mixture thereof in an amount less than 0.3 wt % of the antimicrobial wash, to a biofilm attached or adhered to a surface of human or animal sinus cavity tissue, to detach, remove or otherwise disrupt at least a part of the biofilm, wherein the method is non-ciliotoxic.
A method for removing biofilm comprising:
- applying using sinus irrigation and pressure of about 30,000 Pascal (4.4 psi) to about 480,000 Pascal (70 psi) an antimicrobial wash comprising a non-ciliotoxic concentration of a biguanide compound or mixture thereof to a biofilm attached or adhered to a surface of human or animal sinus cavity tissue, to detach, remove or otherwise disrupt at least a part of the biofilm, wherein the method is non-ciliotoxic.
A method for sinus irrigation comprising:
- applying to a treatment site within a sinus cavity using a sinus irrigator and pressure of about 30,000 Pascal (4.4 psi) to about 480,000 Pascal (70 psi) an antimicrobial wash comprising a non-ciliotoxic concentration of a biguanide compound or mixture thereof, wherein the method is non-ciliotoxic.
A method for treating rhinosinusitis and other bacterial sinus conditions, which method comprises:
- applying with a pressure of about 30,000 Pascal (4.4 psi) to about 480,000 Pascal (70 psi) an antimicrobial wash comprising a biguanide compound or mixtures thereof in an amount less than 0.3 wt % of the antimicrobial wash, to a treatment site within a nasal or sinus cavity;
- and detaching, removing or otherwise disrupting bacteria within the nasal or sinus cavity to provide a greater than 1-log order reduction in one or more of Staphylococcus aureus, Pseudomonas aeruginosa, Staphylococcus epidermidis, Escherichia coli Staphylococcus pneumonia, Haemophilus influenzae or Moraxella catarrhalis bacteria, wherein the method is non-ciliotoxic.
Dependencies are inferred from the claim text.